Preview

Safety and Risk of Pharmacotherapy

Advanced search

Signal Messages in Pediatric Practice

https://doi.org/10.30895/2312-7821-2018-6-4-180-186

Abstract

Abstract. Detection and analysis of drug safety signals in children is a mandatory part of pharmacovigilance. The criteria for evaluating signals of adverse effects were considered. Spontaneous reports databases as a source for detecting signaling information about adverse reactions, including in children were used. More than 17.5 million cases of adverse reactions identified in WHO global database of individual case safety reports — VigiBase which was detected since 1968 in 120 countries — members of the WHO Drug Treatment Control Program. Of these, 1.5 million cases of adverse reactions occur in childhood. Objective: search and analysis for signal information in the post-marketing period of the use of drugs in children to increase the safety of pharmacotherapy in pediatric practice. Results: а causal relationship between desloratadine and weight gain was detected. Desloratadine is an active metabolite of loratadine so the researchers have considered reports on desloratadine and also on loratadine. In VigiBase there are reports of weight gain when taking desloratadine (44 messages) and loratadine (115 messages) in 2016. Among them, 22 reports on weight gain in children from 2 to 11 years. The Pharmacovigilance Risk Assessment Committee of the European Medical Agency (PRAC EMA) recommended marketing authorization holders to add an information about weight gain in children in prescribing information of drugs which contains desloratadine and loratadine. In September 2017, the Committee on Drugs for Human Use, following a review and analysis of VigiBase, approved the recommendations of PRAC EMA. Appropriate changes were made to the instructions for medical use for loratadine tablets. Conclusions. These results confirm the importance of long post-marketing studies, the results of which will provide significant assistance in improving the safety of pharmacotherapy in children.

About the Authors

G. V. Kutekhova
Scientific Centre for Expert Evaluation of Medicinal Products, Moscow
Russian Federation
Analyst of the 1st category of the Department for Expert Analysis of Medicinal Products’ Safety of the Division for Evaluation of Medicinal Products’ Safety


E. O. Zhuravleva
Scientific Centre for Expert Evaluation of Medicinal Products, Moscow
Russian Federation
Head of the Department for Expert Analysis of Medicinal Products’ Safety of the Division for Evaluation of Medicinal Products’ Safety


M. A. Darmostukova
Scientific Centre for Expert Evaluation of Medicinal Products, Moscow
Russian Federation
Senior Analyst of the Department for Evaluation of MIBPs Side Effects of the Division for Evaluation of Medicinal Products’ Safety


I. I. Snegireva
Scientific Centre for Expert Evaluation of Medicinal Products, Moscow
Russian Federation
Cand. Sci. (Med.), Head of the Department for Evaluation of MIBPs Side Effects of the Division for Evaluation of Medicinal Products’ Safety


N. Yu. Velts
Scientific Centre for Expert Evaluation of Medicinal Products, Moscow
Russian Federation
Cand. Sci. (Biol.), Assistant Professor, Senior Analyst of the Department of Expert Analysis Methodology of the Division for Evaluation of Medicinal Products’ Safety


R. N. Alyautdin
Scientific Centre for Expert Evaluation of Medicinal Products, Moscow
Russian Federation
MD, Dr. Sci. (Med.), Professor, Head of the Division for Evaluation of Medicinal Products’ Safety


E. V. Shubnikova
Scientific Centre for Expert Evaluation of Medicinal Products, Moscow
Russian Federation
Cand. Sci. (Med.), Senior Analyst of the Department of Expert Analysis Methodology of the Division for Evaluation of Medicinal Products’ Safety


References

1. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008. Allergy. 2008;63(Suppl. 86):8–160. https://doi.org/10.1111/j.1398-9995.2007.01620.x

2. Zhuravleva EO, Velts NY, Kutekhova GV, Darmostukova MA, Alyautdin RN. Signal as a tool of the pharmacovigilance. Bezopasnost’ i risk farmakotherapii = Safety and Risk of Pharmacotherapy. 2018;6(2):61–7 (In Russ.)]. https://doi.org/10.30895/2312-7821-2018-6-2-61-67

3. Volosovets GG, Dushkina AE, Nastausheva TL. Infant obesity: risk factors, problems and treatment and prophylaxis prospects. Vestnik novykh meditsinskikh tekhnologij = Journal of New Medical Technologies. 2010;17(2):74–6 (In Russ.)

4. Astakhova AV, Lepakhin VK. Lekarstva. Neblagopriyatnye pobochnye reaktsii i kontrol’ bezopasnosti= Medicines. Adverse reactions and safety control. Moscow: Eksmo; 2008 (In Russ.)

5.

6. Kutekhova GV, Lepakhin VK, Romanov BK. Detection of violations in prescribing medicines (off-label prescriptions) in pediatric patients. Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo primeneniya = The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. 2012;(3):23–7 (In Russ.)

7. Viola E, Conforti А. Desloratadine, loratadine and weight increase in children. WHO Pharmaceuticals Newsletter 2017;4:15–9. Available from: http://apps.who.int/iris/bitstream/handle/10665/258800/WPN-2017-04-eng.pdf?sequence=1

8. Khaitov RM, Il’ina NI, eds. Allergologiya i immunologiya: natsional’noye rukovodstvo = Allergology and immunology: national guidance. Moscow: GEOTAR-Media; 2009 (In Russ.)

9. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008. Allergy. 2008;63(Suppl. 86):8–160. https://doi.org/10.1111/j.1398-9995.2007.01620.x

10. Volosovets GG, Dushkina AE, Nastausheva TL. Infant obesity: risk factors, problems and treatment and prophylaxis prospects. Vestnik novykh meditsinskikh tekhnologij = Journal of New Medical Technologies. 2010;17(2):74–6 (In Russ.)

11.


Review

For citations:


Kutekhova G.V., Zhuravleva E.O., Darmostukova M.A., Snegireva I.I., Velts N.Yu., Alyautdin R.N., Shubnikova E.V. Signal Messages in Pediatric Practice. Safety and Risk of Pharmacotherapy. 2018;6(4):180-186. (In Russ.) https://doi.org/10.30895/2312-7821-2018-6-4-180-186

Views: 1390


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2312-7821 (Print)
ISSN 2619-1164 (Online)